BioVie Long-Term Debt 2011-2026 | BIVI

Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.

Main characteristics:

Term exceeds 12 months
Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
Repaid through regular payments (interest and/or principal) over several years

Why long-term debt is needed:

Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital.
Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks.
Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.

A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.

If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.

It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.

Examples of long-term debt:

Mortgage loans for property purchases
Corporate bonds issued by a company to raise capital
Project financing — long-term loans for building or expanding production facilities
Leasing obligations for equipment or transport

Annual Long-Term Debt BioVie

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
275 K	350 K	42.5 K	87.4 K	-	62.5 K	-	826 K	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
826 K	42.5 K	274 K

Quarterly Long-Term Debt BioVie

2025-Q4	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
233 K	254 K	275 K	296 K	315 K	333 K	350 K	366 K	-	30.2 K	42.5 K	54.5 K	65.8 K	76.8 K	87.4 K	97.8 K	-	-	-	62.5 K	62.5 K	62.5 K	62.5 K	62.5 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
366 K	30.2 K	159 K

Long-Term Debt of other stocks in the Biotechnology industry

Issuer	Long-Term Debt	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	273 M	-	2.43 %	$ 254 M	Germany
Verastem VSTM	40.7 M	$ 5.04	-4.73 %	$ 349 M	USA
VistaGen Therapeutics VTGN	948 K	$ 0.57	-5.87 %	$ 17.6 M	USA
Akero Therapeutics AKRO	529 K	-	-	$ 3.67 B	USA
I-Mab IMAB	68.2 M	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	2.42 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	173 M	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	1.83 M	-	-13.47 %	$ 169 M	France
Aileron Therapeutics ALRN	69 K	-	10.36 %	$ 9.8 M	USA
Midatech Pharma plc MTP	4.76 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	278 K	-	-1.52 %	$ 24.7 M	USA
Aptinyx APTX	22.1 M	-	-39.0 %	$ 4.57 M	USA
Avenue Therapeutics ATXI	2.03 M	-	-52.27 %	$ 4.45 M	USA
Институт стволовых клеток человека ISKJ	175 M	-	-	-	Russia
Adaptive Biotechnologies Corporation ADPT	127 M	$ 12.41	-11.1 %	$ 1.88 B	USA
Xenon Pharmaceuticals XENE	7.65 M	$ 54.48	-1.89 %	$ 4.24 B	Canada
BeiGene, Ltd. BGNE	962 M	-	0.49 %	$ 251 B	Cayman-islands
ChemoCentryx CCXI	4.72 M	-	-	$ 3.74 B	USA
Enochian Biosciences ENOB	425 K	-	-	$ 40.5 M	USA
CureVac N.V. CVAC	25.4 M	-	-	$ 867 M	Germany
Summit Therapeutics SMMT	17.5 M	$ 16.58	-3.94 %	$ 12.4 B	Britain
Bellerophon Therapeutics BLPH	203 K	-	-74.18 %	$ 955 K	USA
Alnylam Pharmaceuticals ALNY	1.01 B	$ 317.36	-3.29 %	$ 41.6 B	USA
Arbutus Biopharma Corporation ABUS	806 K	$ 4.29	-3.6 %	$ 822 M	Canada
Allakos ALLK	38.2 M	-	-	$ 28.6 M	USA
Brickell Biotech BBI	146 K	-	-5.38 %	$ 6.06 M	USA
Allena Pharmaceuticals ALNA	210 K	-	3.16 %	$ 1.9 M	USA
Calithera Biosciences CALA	1.67 M	-	-10.95 %	$ 876 K	USA
Fusion Pharmaceuticals FUSN	34.8 M	-	-	$ 1.41 B	Canada
Ampio Pharmaceuticals AMPE	274 K	-	-11.43 %	$ 502 K	USA
AlloVir ALVR	1.13 M	-	4.14 %	$ 49.1 M	USA
Amphastar Pharmaceuticals AMPH	620 M	$ 19.01	-2.66 %	$ 889 M	USA
Gritstone Oncology GRTS	40.1 M	-	0.42 %	$ 213 M	USA
Завод ДИОД DIOD	7.45 M	-	-	-	Russia
Фармсинтез LIFE	13.2 M	-	-	-	Russia
ACADIA Pharmaceuticals ACAD	42 M	$ 20.75	-3.35 %	$ 3.44 B	USA
Aligos Therapeutics ALGS	122 K	$ 6.66	-5.4 %	$ 65.8 M	USA
Teligent, Inc. TLGT	137 M	-	-13.85 %	$ 16.1 M	USA
Aravive ARAV	1.88 M	-	-13.39 %	$ 1.45 M	USA
Alkermes plc ALKS	63.3 M	$ 29.39	-1.77 %	$ 4.84 B	Irlanda
Cabaletta Bio CABA	2.88 M	$ 2.68	-4.96 %	$ 269 M	USA
AbbVie ABBV	64.5 B	$ 209.4	-0.81 %	$ 370 B	USA
AbCellera Biologics ABCL	137 M	$ 3.27	-2.39 %	$ 977 M	Canada
ARCA biopharma ABIO	755 K	-	1052.0 %	$ 415 M	USA
Acer Therapeutics ACER	146 K	-	2.71 %	$ 14 M	USA
Acorda Therapeutics ACOR	167 M	-	-24.86 %	$ 820 K	USA
Acasti Pharma ACST	410 K	-	4.01 %	$ 150 M	Canada
Athira Pharma ATHA	803 K	-	-	$ 269 M	USA
Adverum Biotechnologies ADVM	86 M	-	-	$ 86.2 M	USA